Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Enanta Pharmaceuticals (ENTA) Profit After Tax (2016 - 2025)

Historic Profit After Tax for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q4 2025 value amounting to -$11.9 million.

  • Enanta Pharmaceuticals' Profit After Tax rose 4644.24% to -$11.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$71.5 million, marking a year-over-year increase of 3182.28%. This contributed to the annual value of -$81.9 million for FY2025, which is 2943.34% up from last year.
  • As of Q4 2025, Enanta Pharmaceuticals' Profit After Tax stood at -$11.9 million, which was up 4644.24% from -$18.7 million recorded in Q3 2025.
  • In the past 5 years, Enanta Pharmaceuticals' Profit After Tax registered a high of -$11.9 million during Q4 2025, and its lowest value of -$39.1 million during Q2 2023.
  • Over the past 5 years, Enanta Pharmaceuticals' median Profit After Tax value was -$27.2 million (recorded in 2022), while the average stood at -$26.8 million.
  • In the last 5 years, Enanta Pharmaceuticals' Profit After Tax tumbled by 26711.07% in 2021 and then soared by 4644.24% in 2025.
  • Over the past 5 years, Enanta Pharmaceuticals' Profit After Tax (Quarter) stood at -$30.1 million in 2021, then increased by 3.75% to -$29.0 million in 2022, then fell by 15.25% to -$33.4 million in 2023, then surged by 33.28% to -$22.3 million in 2024, then soared by 46.44% to -$11.9 million in 2025.
  • Its Profit After Tax was -$11.9 million in Q4 2025, compared to -$18.7 million in Q3 2025 and -$18.3 million in Q2 2025.